-
Uncategorized2 weeks agoCollaboration to advance precision oncology therapy
Oncology company One-carbon Therapeutics has entered a strategic collaboration with precision medicine company Tempus AI to advance precision oncology development. The collaboration will leverage Tempus’ proprietary,...
-
Endpoints News2 weeks ago
Sanofi extends $180M to California T cell engager startup Kali
Sanofi is back in the T cell engager business after a couple years of fluctuating interest, extending its support to a relatively unknown California startup in...
-
STAT News – Biotech2 weeks agoSTAT+: Insmed drug benefits patients with rare, bacterial lung disease, study shows
Insmed said Monday that the addition of its drug Arikayce to a standard treatment for patients with a rare bacterial lung disease improved respiratory symptoms and...
-
Endpoints News2 weeks ago
Pfizer’s Lyme disease vaccine trial hampered by lack of cases
Pfizer’s final-stage trial of its long-awaited Lyme disease vaccine missed its primary endpoint, but the drugmaker said it still plans to try to take the experimental...
-
STAT News – Biotech2 weeks agoSTAT+: Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle
An experimental vaccine from Pfizer and Valneva reduced the risk of developing Lyme disease by more than 70%, according to newly released data. Though results appear...
-
STAT News – Biotech2 weeks agoSTAT+: Apogee Therapeutics data show long-acting eczema drug induced relief with less frequent injections
An experimental, long-acting treatment for eczema from Apogee Therapeutics induced skin and itch relief comparable to current, widely used medicines but with less frequent injections, a...
-
Fierce Biotech2 weeks ago
Stryker continues to bring hacked systems back online after patients delay surgeries
Stryker said its manufacturing capacity is ramping up quickly as plants are brought back online as well as electronic ordering and shipping.
-
Uncategorized2 weeks agoIsomAb appoints CEO to lead development of angina treatment
Biotechnology company IsomAb has appointed Dr Philip Brainin as Chief Executive Officer as it looks to enter clinic with a treatment for chronic stable angina (CSA). ...
-
Fierce Biotech2 weeks ago
Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&D
Novartis is investing more than 3.3 billion Chinese yuan (roughly $480 million) to soup up its manufacturing facility in Beijing and strengthen its R&D campus in...
-
Uncategorized2 weeks agoClot-busting drug could harm stroke treatment response
A clot-busting drug may stop promising stroke medicine from working properly, research reveals. Researchers at the University of Manchester found the clot-busting therapy, known as tissue...
High-Throughput Platform for Fast-Acting Covalent Protein Therapies
Terns rebuffed a higher bid before selling to Merck
